Effect of NMN Supplementation on Organ System Biology (VAN)

The Washington University

Status: Completed

Conditions: Glucose Metabolism Disorders

Treatments: Dietary Supplement: Treatment; Other: Placebo

Study type: Interventional

Funder types: Other; Other U.S. Federal agency

Identifiers

NCT04571008

201909118

Details and patient eligibility

About

The goal of this proposal is to determine whether the beneficial effects of NMN on metabolic function observed in rodents applies to people.

Full description

This study is looking at the effect of the dietary supplement "Nicotinamide mononucleotide" (NMN) on key cardiovascular and metabolic functions, specifically those that are important risk factors for diabetes and cardiovascular disease.

Enrollment: 56 patients

Sex: All

Ages: 45 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• BMI 25.0-50.0 kg/m²
• Prediabetes defined as fasting plasma glucose of ≥100 mg/dL, or HbA1C ≥5.7, or HOMA-IR ≥2.5.

Exclusion criteria

• Women who are still having menses
• Persons who take niacin, nicotinamide, or other vitamin B3-related supplementation and are not willing to discontinue supplementation for 3 weeks before medical screening and during the entire study period
• Persons who consume moderate-large amounts of caffeine daily (>2 cups of coffee or 8 oz caffeinated drinks per day) or consume less amounts of caffeine but believe withdrawal symptoms (e.g. headache) are likely if caffeine is stopped
• Unstable weight (>3% change during the last 2 months before entering the study)

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

56 participants in 2 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

At least 16 weeks of placebo.

Treatment:

Other: Placebo

NMN supplementation

Experimental group

Description:

At least 16 weeks of NMN.

Treatment:

Dietary Supplement: Treatment